Asset
Zanzalintinib
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03845166 | phase1 | active_not_recruiting | 2019-03-20 | 2026-08-31 | Exelixis | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors |
| NCT05425940 | phase3 | active_not_recruiting | 2022-09-07 | 2026-06-16 | Exelixis | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer |
| NCT05678673 | phase3 | active_not_recruiting | 2023-01-01 | 2026-12-15 | Exelixis | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma |
FDA applications (0)
This company has no applications containing this asset.